(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 3.62% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 5.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Gilead Sciences's revenue in 2025 is $28,863,000,000.On average, 30 Wall Street analysts forecast GILD's revenue for 2025 to be $36,482,204,944,232, with the lowest GILD revenue forecast at $34,663,182,005,376, and the highest GILD revenue forecast at $38,194,518,488,312. On average, 30 Wall Street analysts forecast GILD's revenue for 2026 to be $37,855,778,200,244, with the lowest GILD revenue forecast at $34,864,192,725,768, and the highest GILD revenue forecast at $40,305,131,052,428.
In 2027, GILD is forecast to generate $40,007,337,392,588 in revenue, with the lowest revenue forecast at $37,201,872,955,512 and the highest revenue forecast at $42,404,576,354,300.